An Acadia Pharmaceuticals drug that’s already approved for psychosis associated with Parkinson’s disease could soon be heading to an FDA review to expand the use of the drug to dementia patients.
On Monday, Acadia (NASDAQ: ACAD) reported that its drug, pimavanserin, met the goal of delaying relapse of psychosis in dementia patients compared to a placebo. Based on the results, the San Diego company said it would end the study early and seek a meeting with the regulator to discuss filing next year for approval in dementia-related psychosis.
Pimavanserin was approved in 2016 as a treatment for psychosis associated with… Read more »
UNDERWRITERS AND PARTNERS
